| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INSP | Common Stock | Options Exercise | $355K | +5K | +43.94% | $71.00 | 16.4K | Aug 22, 2024 | Direct | F1 |
| transaction | INSP | Common Stock | Sale | -$227K | -1.2K | -7.33% | $189.16 | 15.2K | Aug 22, 2024 | Direct | F2 |
| transaction | INSP | Common Stock | Sale | -$722K | -3.8K | -25.03% | $190.04 | 11.4K | Aug 22, 2024 | Direct | F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | INSP | Employee Stock Option (Right to Buy) | Options Exercise | $0 | -5K | -40.82% | $0.00 | 7.25K | Aug 22, 2024 | Common Stock | 5K | $71.00 | Direct | F4 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Includes 109 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan since the Reporting Person's Form 4 dated March 26, 2024. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $188.51 to $189.35. The Reporting Person undertakes to provide Inspire Medical Systems, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.51 to $190.37. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F4 | The option is fully vested and exercisable. |
All transactions reported herein were made pursuant to a Rule 10b5-1 trading plan dated May 23, 2024.